CVE-2026-123051: The REV.exe module distributed with Farmasimplex contains embedded OAuth client credentials for
Source GCVE Database
Not known to be exploited · CVSS 1.2 Low : upgrade to 16.2.0 when convenient.
Data as of 17 Nov 2026, 16:51 UTC
Thin evidence
One scorer or none| CNA (ENISA) | CVSS 4.0 | 1.2 |
|---|
- Patch
- Available – fixed in 16.2.0
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:UExploitation evidence
Disclosed: evidence found.
CVE published 17 Nov 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 16 Nov 2026.
What to do
Upgrade Farmasimplex REV.exe to 16.2.0.
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| CIPCarbone srlFarmasimplex REV.exe | Affected
| Fixed in
|
AI-suggested
Mitigation should focus on restricting access to the REV.exe executable to trusted users only and implementing additional authentication controls around the OAuth integration to limit the potential misuse of extracted credentials.
Description
The REV.exe module distributed with Farmasimplex contains embedded OAuth client credentials for integration with the IZS platform. An attacker who gains access to this executable could extract these credentials and potentially reuse them to access integration resources or manipulate associated information, depending on the privileges and authentication controls in place. This vulnerability is identified as CVE-2026-123051 and has a medium severity rating.